Effects of race on survival after stem cell transplantation.

[1]  J. Fay,et al.  Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. , 2005, Blood.

[2]  Edward J. Lee,et al.  Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. , 2004, Blood.

[3]  S. Srinivasula,et al.  Differential modulation of endotoxin responsiveness by human caspase-12 polymorphisms , 2004, Nature.

[4]  Ming-Tseh Lin,et al.  Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. , 2003, The New England journal of medicine.

[5]  J. Klein,et al.  Trends in survival rates after allogeneic hematopoietic stem-cell transplantation for acute and chronic leukemia by ethnicity in the United States and Canada. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Weinshilboum.  Inheritance and drug response. , 2003, The New England journal of medicine.

[7]  M. Caudill,et al.  Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. , 2003, Journal of the American Dietetic Association.

[8]  A. Recht,et al.  Race, socioeconomic status, and breast carcinoma in the U.S. , 2002, Cancer.

[9]  N. Heerema,et al.  Racial and ethnic differences in survival of children with acute lymphoblastic leukemia. , 2002, Blood.

[10]  D. Harlan,et al.  Ethnicity Greatly Influences Cytokine Gene Polymorphism Distribution , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  Colin B Begg,et al.  Survival of blacks and whites after a cancer diagnosis. , 2002, JAMA.

[12]  D. Harlan,et al.  Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. , 2001, Transplantation.

[13]  D. Confer.  The National Marrow Donor Program , 2001, Cancer.

[14]  J. Jones,et al.  Assessment of barriers to bone marrow donation by unrelated African-American potential donors. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  C. Young,et al.  Renal transplantation in black Americans. , 2000, The New England journal of medicine.

[16]  M. Boeckh,et al.  Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. , 2000, Blood.

[17]  C. Pettaway.  Racial differences in the androgen/androgen receptor pathway in prostate cancer. , 1999, Journal of the National Medical Association.

[18]  Xin Qun Wang,et al.  Racial disparities in renal transplant outcomes. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  W. Hughes.  Use of dapsone in the prevention and treatment of Pneumocystis carinii pneumonia: a review. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  K. Boucher,et al.  HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. , 1997, Transplantation.

[21]  D. Watkins,et al.  Heirs of the jaguar and the anaconda: HLA, conquest and disease in the indigenous populations of the Americas. , 1997, Tissue antigens.

[22]  T. Ohta,et al.  Episodic evolution and turnover of HLA-B in the indigenous human populations of the Americas. , 1997, Tissue antigens.

[23]  H. Deeg,et al.  Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. , 1997, Blood.

[24]  M. Boeckh,et al.  Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. , 1996, Blood.

[25]  J. Scott,et al.  Bone marrow transplantation for sickle cell disease. , 1996, The New England journal of medicine.

[26]  D. Pearl,et al.  The incidence of the gene for thermolabile methylene tetrahydrofolate reductase in African Americans. , 1996, Thrombosis research.

[27]  T. Ohta,et al.  Population Biology of Antigen Presentation by MHC Class I Molecules , 1996, Science.

[28]  K. Dusenbery,et al.  Related donor marrow transplant for chronic myeloid leukemia: patient characteristics predictive of outcome. , 1996, Bone marrow transplantation.

[29]  R. Wolfe,et al.  Inferior outcome of two-haplotype matched renal transplants in blacks: role of early rejection. , 1995, Kidney international.

[30]  H. Deeg,et al.  A toxicity study of trimetrexate used in combination with cyclosporine as acute graft-versus-host disease prophylaxis in HLA-mismatched, related donor bone marrow transplants. , 1995, Transplantation.

[31]  R A Nash,et al.  Tacrolimus (FK506) alone or in combination with methotrexate or methylprednisolone for the prevention of acute graft-versus-host disease after marrow transplantation from HLA-matched siblings: a single-center study. , 1995, Blood.

[32]  H. Deeg,et al.  Marrow transplantation for patients in accelerated phase of chronic myeloid leukemia. , 1994, Blood.

[33]  K. Sullivan,et al.  Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  J. Holland,et al.  Socioeconomic status and cancer survival. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Kimball,et al.  Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. , 1991, Transplantation.

[36]  H. Deeg,et al.  Is race a risk factor for allogeneic marrow transplantation? , 1986, Bone marrow transplantation.

[37]  H. Deeg,et al.  Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. , 1986, The New England journal of medicine.